

Receipt date: 03/22/2006

10521929 - GAU: 1614

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32586A
APPLICATION NO.
10/521,929
APPLICANT
OHTSURU ET AL.
FILING DATE
AUGUST 5, 2005

Group

Exr. Leslie A. Royds, AU 1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	* WO 99/03854	01/28/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	* EP 0 564 409 [in German; English claims equivalent in AU-B-35694/93]	10/06/93	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AO	* AU-B-35694/93 [English claims corresponding to EP 0 546 409]	10/07/93	Australia			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cohen, Residence in General Surgery, Homepage of the Washington University School of Medicine, Dept. of Surgery (1997, 1998).
	AS	* Cohen et al., "Inhibition of Medullary Thyroid Carcinoma Cell Proliferation and RET Phosphorylation by Tyrosine Kinase Inhibitors", <i>Surgery</i> , Vol. 132, No. 6, pp. 960-968 (2002).
	AT	Eng, "Biology of Neoplasia. RET Proto-Oncogene in the Development of Human Cancer", <i>J Clin Oncol</i> , Vol. 17, No. 1, pp. 380-393 (1999).

EXAMINER /Leslie A. Royds/ (02/18/2009)

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (02/18/2009)

Receipt date: 03/22/2006

10521929 - GAU: 1614

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32586A
APPLICATION NO.
10/521,929
APPLICANT
OHTSURU ET AL.
FILING DATE
AUGUST 5, 2005

Group

Exr. Leslie A. Royds, AU 1614

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Fagin, "Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer--Insights into Pathogenesis and Tumor-specific Therapeutic Targets", <i>Endocrinology</i> , Vol. 143, No. 6, pp. 2025-2028 (2002).
DB	Frasca et al., "Tyrosine Kinase Inhibitor STI571 Enhances Thyroid Cancer Cell Motile Response to Hepatocyte Growth Factor", <i>Oncogene</i> , Vol. 20, No. 29, pp. 3845-3856 (2001).
DC	* Joensuu and Dimitrijevic, "Tyrosine Kinase Inhibitor Imatinib (STI571) as an Anticancer Agent for Solid Tumours", <i>Ann Med</i> , Vol. 33, No. 7, pp. 451-455 (2001).
DD	Loré, Talidis, Di Cairano and Renieri, "Multiple Endocrine Neoplasia Type 2 Syndromes May be Associated with Renal Malformations", <i>J Intern Med</i> , Vol. 250, No. 1, pp. 37-42 (2001).
DE	Meric et al., "Expression Profile of Tyrosine Kinases in Breast Cancer", <i>Clin Cancer Res</i> , Vol. 8, No. 2, pp. 361-367 (2002).
DF	* Podtcheko et al., "The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells", <i>J Clin Endocrinol Metab</i> , Vol. 88, No. 4, pp. 1889-1896 (2003).
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER /Leslie A. Royds/ (02/18/2009)

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (02/18/2009)